Pharmacokinetics of sapropterin in patients with phenylketonuria

Clinical Pharmacokinetics

Volumn 47, Issue 12, 2008, Pages 817-825

  Feillet, François ^a   Clarke, Lorne ^b   Meli, Concetta ^c   Lipson, Mark ^d   Morris, Andrew A ^e   Harmatz, Paul ^f   Mould, Diane R ^g   Green, Bruce ^g   Dorenbaum, Alex ^h   Giovannini, Marcello ⁱ   Foehr, Erik ^h  

^a HÔPITAL D ENFANTS   (France)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Azienda Ospedaliera Universitaria   (Italy)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g Projections Research Inc   (United States)

^h BIOMARIN PHARMACEUTICAL INC   (United States)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

Phenylketonuria; Sapropterin, pharmacokinetics

Indexed keywords

KUVAN; PHENYLALANINE; PTERIN DERIVATIVE; SAPROTERIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHENYLKETONURIA; PRIORITY JOURNAL; SCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; BIOPTERIN; BODY WEIGHT; CHILD; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHENYLALANINE; PHENYLKETONURIAS; UNITED STATES; YOUNG ADULT;

EID: 56749139651     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200847120-00006     Document Type: Article

References (19)

1. Donlon J, Levy HL, Scriver CR. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Companies, Inc., 2001: 1667-724
2. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement. Phenylketonuria: screening and management. Pediatrics 2001 Oct; 108 (4): 972-82
3. Hennermann JB, Buhrer C, Blau N, et al. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 2005 Dec; 86 Suppl. 1: S86-90
4. Lambruschini N, Perez-Duenas B, Vilaseca MA, et al. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 2005 Dec; 86 Suppl. 1: S54-60
5. Trefz FK, Scheible D, Frauendienst-Egger G, et al. Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Mol Genet Metab 2005 Dec; 86 Suppl. 1: S75-80
6. Lee P, Treacy EP, Crombez E, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A 2008 Oct 16; 146A (22): 2851-9
7. Burton B, Grange D, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007 Oct; 30 (5): 700-7
8. Levy H, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007 Aug; 370 (9586): 504-10
9. Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn 2003 Apr; 30 (2): 145-61
10. Fiege B, Ballhausen D, Kierat L, et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab 2004 Jan; 81 (1): 45-51
11. Fukushima T, Nixon JC. Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 1980 Feb; 102 (1): 176-88
12. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm Oct 1992; 20 (5): 511-28
13. Gobburu JV, Lawrence J. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm Res 2002 Jan; 19 (1): 92-8
14. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001 Jun; 28 (3): 231-52
15. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994 Apr; 22 (2): 165-77
16. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 Apr; 28 (2): 171-92
17. Ritschel W. Handbook of basic pharmacokinetics. 2nd ed. Hamilton (IL): Drug Intelligence Publications, 1980: 413-26
18. Fiege B, Bonafe L, Ballhausen D, et al. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol Genet Metab 2005 Dec; 86 Suppl. 1: S91-5
19. Matalon R, Koch R, Michals-Matalon K, et al. Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 2004 Jan-Feb; 6 (1): 27-32